DANA; A Tool to Detect Cognitive Changes in Pre-clinical and MCI Patients

项目摘要/摘要 本次提出的二期工程的目标是发展数字化自动化 将神经行为评估(DANA)应用程序集成到患者易于使用的工具中 患有轻度认知障碍(MCI)和阿尔茨海默病(AD)，并可提供 临床医生在跟踪和诊断这些疾病方面拥有有意义的数据。丹娜 是FDA批准的神经认知评估工具，以前曾用于 已被证明是一种有效和可靠的筛查方法 认知功能和跟踪认知功能随时间的变化。 该提案的具体目标是：在第一阶段(1)确定技术可行性和 DANA高频认知测试的诊断准确性；第二阶段(2) 家庭使用DANA的技术开发；以及(3)建立预测效度 达纳为阿尔茨海默病的早期检测提供了帮助。 在第一阶段，该项目将实施一项试点研究。MCI患者和正常对照组将 无论是在门诊还是在家中，都要带上Dana，以检验这一方法的可行性 在家中使用Dana的人群和Dana区分健康的能力 和受损用户。 在第二阶段，该项目将以第一阶段的成果为基础，从技术上完善DANA 更好地满足MCI患者需求的工具。改进后的应用程序将部署在 实验，包括MCI患者和正常对照组，将建立预测 DANA在阿尔茨海默病早期检测中的有效性。

Project Summary/Abstract The goal of this proposed two phase project is to develop the Digital Automated Neurobehavioral Assessment (DANA) app into a tool that can be easily used by patients with Mild Cognitive Impairment (MCI) and Alzheimer’s disease (AD) and can provide clinicians with meaningful data in the tracking and diagnosis of these conditions. DANA is an FDA-cleared neurocognitive assessment tool that has been previously used with similar populations and has been shown to be a valid and reliable method for screening cognitive functioning and tracking changes in cognitive functioning over time. The specific aims of the proposal are: in Phase I (1) Determine technical feasibility and diagnostic accuracy of high-frequency cognitive testing with DANA; in Phase II (2) Technical development of DANA for in-home use; and (3) Establish predictive validity of DANA for the early detection of Alzheimer’s disease. In Phase I, this project will implement a pilot study. MCI patients and normal controls will take DANA both in-clinic and at home in order to examine the feasibility of this population using DANA in the home and DANA’s ability to discriminate between healthy and impaired users. In Phase II, this project will build on the results of Phase I to technically refine the DANA tool to better fit the needs of MCI patients. The refined app will be deployed in an experiment, involving MCI patients and normal controls, that will establish the predictive validity of DANA for the early detection of Alzheimer’s disease.